Case study

Keryx Biopharmaceuticals

Supporting the first simultaneous NASDAQ/ AIM listing for a biotech start-up company

PA supported the listing of Keryx Pharmaceuticals by providing third-party due diligence on its technology and products, explaining the science in a language that investors could understand.

PA's independent expert's report is included in the issue document, designed to meet both UK and US requirements. The inclusion of such third-party due diligence is unique in an offer document for an initial offering on the US stock market.